Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Valneva

The First Lyme Disease Vaccine in 24 Years Just Passed Its Pivotal Phase 3 Trial with 74 Percent Efficacy — and It Is for Children Too

Pfizer and Valneva announced Phase 3 VALOR trial results for Lyme disease vaccine PF-07307405 on March 23, 2026: 73.2–74.8% efficacy in ages 5 and older. Regulatory submissions planned for 2026. No Lyme vaccine has been available in the U.S. since 2002.

Medical Daily · Jun 12

Valneva Q1 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

MarketBeat · May 13

He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified

Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…

The Mary Sue · Apr 1

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.

Euronews · Mar 23

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga · Nov 26, 2025

France faces record chikungunya cases as US suspends vaccine licence

Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the country. At the same time, US regulators have suspended the licence of a French-made vaccine after reports of serious side effects.

Radio France Internationale · Aug 26, 2025

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.

Benzinga · Aug 25, 2025

Read news from The Economist, FT, and more,
with one subscription

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Benzinga · Dec 3, 2024

Worst of Westminster: Labour Lords U-turn and interest rates hike

Good evening and welcome to the latest edition of The Worst of Westminster! The week kicked off with MPs voting overwhelmingly to approve the…

The National (Scotland) · Jun 23, 2023

Axed Livingston Covid vaccine contract cost taxpayers £358million

The contract was axed by ministers in 2021

Daily Record · Jun 22, 2023

Axed Livingston Covid vaccine contract cost taxpayers £358million

French firm Valneva was supposed to manufacture more than 100 million vaccines at its site in Livingston but the contract was axed by ministers in 2021.

Daily Record · Jun 21, 2023

Axed Covid vaccine deal with Livingston firm cost taxpayers £358m

THE UK Government has been accused of “absolutely shafting” a Scottish vaccine plant after it emerged a contract it axed cost taxpayers £358.6…

The National (Scotland) · Jun 21, 2023

Axed Covid vaccine contract cost taxpayers £358 million

French company now considering selling the plant specially built in Livingston to manufacture the vaccines

Insider UK · Jun 21, 2023

Axed Covid vaccine contract cost taxpayers £358m

The UK Government pulled out of the deal with French firm Valneva in 2021.

The Independent UK · Jun 21, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

Radio France Internationale · Jun 14, 2023

Vaccine trials against chikungunya virus 'promising', but more research is still needed

Franco-Austrian drugmaker Valneva's vaccine candidate against chikungunya – a mosquito-borne virus that causes occasional outbreaks across the world – has revealed promising results in a wide-ranging new trial.

Benzinga · Sep 20, 2022

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket

Gainers

Benzinga · Aug 18, 2022

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Reuters · Aug 18, 2022

WHO recommends Valneva's COVID vaccine

The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva's COVID-19 vaccine.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU · Aug 9, 2022

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

Benzinga · Aug 9, 2022

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Axios · Aug 8, 2022

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

The Independent UK · Aug 8, 2022

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

Reuters · Aug 8, 2022

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Benzinga · Aug 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Reuters · Jul 20, 2022

EU drops nearly all of its order for Valneva COVID vaccine

The European Commission has dropped nearly all of its order of 60 million doses of a new COVID-19 vaccine from French firm Valneva, the EU executive said on Wednesday, in a move that all but wipes out the shot's value for the company. The EU agreed in November last year…

1 2 3

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.